3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
3
Thoracic
1
Other neoplasm
1
Gynecologic
1
Breast
1
Conditions
Lung Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Small Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Liver Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Brain Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
pembrolizumab
7
Ipilimumab
5
Nivolumab
4
fludarabine
3
Radiosurgery
3
Drug Therapy
3
Cyclophosphamide
3
spartalizumab
2
aldesleukin
2
Sirolimus
2
Riluzole
2
Radiotherapy
2
Psychiatric Rehabilitation
2
Polymerase Chain Reaction
2
Oncolytic Virotherapy
2
Counseling
2
Bupropion
2
Blood Specimen Collection
2
vofatamab
1
utomilumab
1
trastuzumab deruxtecan
1
toripalimab
1
tocilizumab
1
sargramostim
1
saracatinib
1
pertuzumab
1
pazopanib
1
liposomal doxorubicin
1
ixabepilone
1
fostamatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
Mass Spectrometry
×
Thoracic
×
Clear all
NCT00900094
2012-02-07
IRB 2000-294
University of Michigan Rogel Cancer Center
Completed
200 enrolled